Jefferies Group’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-14,000
Closed -$1.57M 1642
2020
Q4
$1.57M Buy
+14,000
New +$1.48M 0.01% 798
2020
Q3
Sell
-11,299
Closed -$870K 1348
2020
Q2
$881 Sell
11,299
-28,644
-72% -$1.94M 0.01% 793
2020
Q1
$2.34M Buy
39,943
+9,560
+31% +$615K 0.03% 611
2019
Q4
$2.43M Buy
30,383
+4,990
+20% +$374K 0.02% 933
2019
Q3
$1.87M Buy
25,393
+13,428
+112% +$1.16M 0.01% 1132
2019
Q2
$1.13M Buy
+11,965
New +$988K 0.01% 1225
2018
Q3
Sell
-500
Closed -$32K 2413
2018
Q2
$32K Buy
+500
New +$39.8K ﹤0.01% 2225

Other funds holding BPMC

Jefferies Group's BPMC Position: Q1 2021 in Review

Jefferies Group sold out of Blueprint Medicines (BPMC) in Q1 2021, closing a stake of 14,000 shares — an estimated $1.57M sold.

Jefferies Group first reported a position in BPMC in Q2 2018 and held it in 7 quarters. The position peaked at $2.43M in Q4 2019. 263 funds tracked by Wall St. Rank hold BPMC as of Q1 2021.

  • Jefferies Group reported no remaining Blueprint Medicines position as of Q1 2021 after selling out during the quarter.
  • Jefferies Group sold 14,000 Blueprint Medicines shares in Q1 2021, an estimated $1.57M.
  • Jefferies Group first reported a position in Blueprint Medicines in Q2 2018 and held it in 7 quarters.
  • Jefferies Group's Blueprint Medicines position peaked at $2.43M in Q4 2019.
  • 263 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.